CN104520296B - 作为ttx-s阻断剂的吡咯并吡啶酮衍生物 - Google Patents

作为ttx-s阻断剂的吡咯并吡啶酮衍生物 Download PDF

Info

Publication number
CN104520296B
CN104520296B CN201380022248.1A CN201380022248A CN104520296B CN 104520296 B CN104520296 B CN 104520296B CN 201380022248 A CN201380022248 A CN 201380022248A CN 104520296 B CN104520296 B CN 104520296B
Authority
CN
China
Prior art keywords
pyridin
dihydro
oxygen
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380022248.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104520296A (zh
Inventor
川村清
森田干雄
山岸龙也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raqualia Pharma Inc
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of CN104520296A publication Critical patent/CN104520296A/zh
Application granted granted Critical
Publication of CN104520296B publication Critical patent/CN104520296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201380022248.1A 2012-04-25 2013-04-25 作为ttx-s阻断剂的吡咯并吡啶酮衍生物 Active CN104520296B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261638085P 2012-04-25 2012-04-25
US61/638,085 2012-04-25
JP2012260231 2012-11-28
JP2012-260231 2012-11-28
PCT/JP2013/002825 WO2013161312A1 (en) 2012-04-25 2013-04-25 Pyrrolopyridinone derivatives as ttx-s blockers

Publications (2)

Publication Number Publication Date
CN104520296A CN104520296A (zh) 2015-04-15
CN104520296B true CN104520296B (zh) 2016-11-16

Family

ID=49482654

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380022248.1A Active CN104520296B (zh) 2012-04-25 2013-04-25 作为ttx-s阻断剂的吡咯并吡啶酮衍生物

Country Status (13)

Country Link
US (1) US9187475B2 (enExample)
EP (1) EP2841435B1 (enExample)
JP (1) JP6175672B2 (enExample)
KR (1) KR102090944B1 (enExample)
CN (1) CN104520296B (enExample)
BR (1) BR112014026283B1 (enExample)
CA (1) CA2871229C (enExample)
ES (1) ES2645984T3 (enExample)
IN (1) IN2014MN02056A (enExample)
MX (1) MX360323B (enExample)
RU (1) RU2646754C2 (enExample)
TW (1) TWI577677B (enExample)
WO (1) WO2013161312A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6173364B2 (ja) * 2014-01-29 2017-08-02 大正製薬株式会社 部分的に飽和された含窒素複素環化合物を有効成分として含有する医薬
US11071793B2 (en) * 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
NZ742351A (en) 2015-11-02 2023-03-31 Blueprint Medicines Corp Inhibitors of ret
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
SG11201906412SA (en) * 2017-01-23 2019-08-27 Revolution Medicines Inc Pyridine compounds as allosteric shp2 inhibitors
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
HUE059057T2 (hu) 2017-05-04 2022-10-28 Bayer Cropscience Ag 2-{[2-(feniloximetil)piridin-5-il]oxi}-etánamin-származékok és rokon vegyületek mint peszticidek, például növényvédelemre
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
KR20210107698A (ko) * 2018-12-26 2021-09-01 라퀄리아 파마 인코포레이티드 Nav1.7 및 Nav1.8 차단제로 쓰이는 헤테로환 유도체
KR20210135521A (ko) 2019-03-06 2021-11-15 다이이찌 산쿄 가부시키가이샤 피롤로피라졸 유도체
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN117777011A (zh) * 2022-09-22 2024-03-29 顺毅宜昌化工有限公司 一种烷氧基取代的吡啶类化合物的制备方法
JP2026513962A (ja) * 2023-04-07 2026-05-01 バイオジェン・エムエイ・インコーポレイテッド 炎症性疾患の処置のためのチロシンキナーゼ２（ＴＹＫ２）阻害剤としての１Ｈ－ピロロ［２，３－ｂ］ピリジン－４－イル］－２－オキソピロリジン－３－カルボニトリル誘導体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083239A1 (en) * 2006-01-23 2007-07-26 Pfizer Limited Pyridine derivatives as sodium channel modulators
US20110034467A1 (en) * 2006-05-31 2011-02-10 Roehrig Susanne Dihydro-pyrrolopyridine-, dihydro-pyrrolopyridazine- and dihydro-pyrrolopyrimidine-derivatives and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002081446A1 (en) * 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2008046046A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
RU2513636C2 (ru) * 2008-01-04 2014-04-20 Интелликайн ЭлЭлСи Некоторые химические структуры, композиции и способы
EP3309152B1 (en) * 2009-12-22 2020-09-09 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
WO2011083316A1 (en) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
KR101458006B1 (ko) 2010-10-18 2014-11-04 라퀄리아 파마 인코포레이티드 Ttx-s 차단제로서의 아릴아미드 유도체
EP2632461A4 (en) * 2010-10-29 2014-04-02 Merck Sharp & Dohme Isoindolinone PDE10 INHIBITORS
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007083239A1 (en) * 2006-01-23 2007-07-26 Pfizer Limited Pyridine derivatives as sodium channel modulators
US20110034467A1 (en) * 2006-05-31 2011-02-10 Roehrig Susanne Dihydro-pyrrolopyridine-, dihydro-pyrrolopyridazine- and dihydro-pyrrolopyrimidine-derivatives and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CpRuCl-catalyzed [2 + 2 + 2] cycloadditions of alpha,omega-diynes with electron-deficient carbon-heteroatom multiple bonds leading to heterocycles;Yoshihiko Yamamoto et al.;《J.AM.CHEM.SOC.》;20041214;第127卷;第608-609页 *
One-Pot Synthesis of 2,3-Dihydro-pyrrolopyridinones Using in Situ Generated Formimines;Geoffrey Deguest et al.;《Organic Letters》;20061115;第8卷(第25期);第5891页 *
Ruthenium-Catalyzed Cycloaddition of 1,6-Diynes and Nitriles under Mild Conditions Role of the Coordinating Group of Nitriles;Yoshihiko Yamamoto et al.;《Chem.Eur.J.》;20061231;第12卷;第5626页 *
Synthesis of Merimines. 7-Chloro-6-methylmerimine and Related Analogs;Shreekrishna M et al.;《GADEKAR,FREDERICK,SEMB AND VAUGHAN》;19610228;第26卷;第472页 *

Also Published As

Publication number Publication date
KR102090944B1 (ko) 2020-03-19
EP2841435B1 (en) 2017-09-06
TWI577677B (zh) 2017-04-11
JP2015514679A (ja) 2015-05-21
WO2013161312A1 (en) 2013-10-31
MX2014012915A (es) 2014-11-25
HK1207381A1 (en) 2016-01-29
IN2014MN02056A (enExample) 2015-08-21
CA2871229A1 (en) 2013-10-31
KR20150006001A (ko) 2015-01-15
CN104520296A (zh) 2015-04-15
US9187475B2 (en) 2015-11-17
US20150094306A1 (en) 2015-04-02
TW201350480A (zh) 2013-12-16
RU2014147243A (ru) 2016-06-10
JP6175672B2 (ja) 2017-08-09
ES2645984T3 (es) 2017-12-11
CA2871229C (en) 2020-10-27
HK1203940A1 (en) 2015-11-06
RU2646754C2 (ru) 2018-03-07
BR112014026283B1 (pt) 2022-08-02
EP2841435A1 (en) 2015-03-04
MX360323B (es) 2018-10-29
EP2841435A4 (en) 2015-11-11
BR112014026283A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
CN106478497B (zh) 作为ttx-s阻滞剂的芳胺衍生物
TWI577677B (zh) 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物
KR102577137B1 (ko) Nav1.7 및 Nav1.8 차단제로 쓰이는 아미드 유도체
CN104364235B (zh) 作为ttx‑s阻断剂的酰胺衍生物
CN104812755B (zh) 作为ttx‑s阻断剂的吡唑并吡啶衍生物
TW201920107A (zh) 作為ttx-s阻斷劑之雙芳氧基衍生物
HK1203940B (en) Pyrrolopyridinone derivatives as ttx-s blockers
HK1230593A1 (en) Arylamide derivatives as ttx-s blockers
HK1187909A (en) Arylamide derivatives as ttx-s blockers
HK1188600B (en) Arylamide derivatives as ttx-s blockers
HK1188600A (en) Arylamide derivatives as ttx-s blockers

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203940

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203940

Country of ref document: HK